Treatment
6Systemic sclerosis therapy reference (2026)
Reference snapshot of systemic sclerosis therapy across organ-domain-specific and emerging disease-modifying tiers.
ANCA-associated vasculitis therapy reference (2026)
Reference snapshot of ANCA-associated vasculitis therapy across induction, maintenance, and refractory disease.
Lupus nephritis therapy reference (2026)
Reference snapshot of lupus nephritis therapy across induction and maintenance phases.
Sjogren disease therapy reference (2026)
Reference snapshot of Sjogren disease therapy across symptomatic, off-label, and emerging mechanism-targeted tiers.
IBD biologic and small-molecule landscape, 2026 mid-year reference
Reference layout of the IBD therapeutic class as of mid-2026: approved biologics (anti-TNF, anti-integrin, IL-12/23, IL-23), oral small molecules (JAK, S1P modulators, TYK2 in pipeline), and the live commercial questions including line-of-therapy positioning and combination strategy.
Psoriasis biologics landscape, 2026 mid-year reference
Reference layout of the psoriasis biologic class as of mid-2026: approved mechanisms, first-line versus later-line positioning, the IL-23 dominance picture, and the live commercial questions for the class.